Trial Profile
An Open-Label, Single and Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-17299425 in Patients With Traumatic Brain Injury
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs JNJ 17299425 (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Apr 2014 New trial record